What would you like us to do with the funds you've selected
Growing sales in emerging markets is vital to top line growth of healthcare holdings, say Polar Capital healthcare investors.
By Jonathan Boyd, Editor-in-Chief, Financial Express Thursday April 29, 2010
Latest results from pharmaceutical sector giant AstraZeneca lend further support to the idea that emerging markets are going to become increasingly important for funds focused on the healthcare sector, say Daniel Mahony and Gareth Powell, managers on the Polar Capital healthcare investment team.
The drugs maker just reported year-on-year growth of 19 per cent from emerging markets. Mahony and Powell estimate that over the next 10 years emerging markets could add $400bn to $500bn to global pharmaceutical sales; this would be a positive step forward for an industry that recently has seen sales in developed markets suffer from a number of key patents expiring. By 2020 the value of pharmaceutical sales in emerging markets could equal that currently seen in the US and Western Europe.
Polar Capital recently announced it is to launch the Polar Capital Global Healthcare Growth and Income Trust, in order to tap into the changes seen occuring in the global healthcare market.
Follow FE Trustnet
Have you been allocating more to cash or equities, given signs of rising risks?
13:00 | Monday, January 20, 2014